Brock J. Sishc

Brock J. Sishc

Auto-generated profile, based on publicly available information

Brock J. Sishc

Department of Cancer Biology and Radiation Oncology, Mayo Clinic, Jacksonville, Florida

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
12 May 2021 in Science Translational Medicine
Verified
Journal Article
Closed access
BSBrock J. Sishc
Brock J. Sishc
LDLianghao Ding
Lianghao Ding
TNTaek-Keun Nam
Taek-Keun Nam
CHCollin D. Heer
Collin D. Heer
SRSamuel N. Rodman
Samuel N. Rodman
MSMichael Story
Michael Story
Avasopasem manganese enhances tumor cell killing after ablative hypofractionated radiation through the generation of hydrogen peroxide.

14 June 2022 in Life Sciences in Space Research
Verified
Journal Article
Open access
BSBrock J. Sishc
Brock J. Sishc
JZJanice Zawaski
Janice Zawaski
JSJanapriya Saha
Janapriya Saha
LCLisa S. Carnell
Lisa S. Carnell
KFKristin M. Fabre
Kristin M. Fabre
SES. Robin Elgart
S. Robin Elgart
NASA's currently planned long-duration, deep space exploration missions outside of low Earth orbit (LEO) will result in the exposure of astronauts to relatively high lifetime doses of ionizing radiation (IR), exceeding what humans have previously encountered in space. Of concern to this exposure are the long-term health consequences of radiation carcinogenesis, cardiovascular and degenerative disease, and central nervous system decrements. Existing engineering solutions are insufficient to decrease the lifetime accumulated IR exposure to levels currently allowable by agency standards, therefore appropriate countermeasure and mitigation strategies must be developed to enable long duration missions. Emerging discoveries in the fields of radiation oncology and the mitigation of Acute Radiation Syndrome (ARS) have demonstrated the potential for compound-based/biological radiomodifiers to drastically improve clinical outcomes and represent a promising strategy for space radiation countermeasure development. This review outlines the unique challenges posed by the space radiation environment, defines the limits of terrestrial radiation protection strategies in space, describes a brief overview of current space radiation countermeasure development strategies, highlights potential new approaches for countermeasure identification and development, and speculates on the potential benefits beyond space exploration.

13 October 2025 in Molecular Cancer Therapeutics
Verified
Journal Article
Open access
KSKaty L. Swancutt
Katy L. Swancutt
EEEslam A. Elghonaimy
Eslam A. Elghonaimy
JNJames H. Nicholson
James H. Nicholson
Laurentiu M. PopLaurentiu M. Pop
Laurentiu M. Pop
BSBrock J. Sishc
Brock J. Sishc
TATodd A. Aguilera
Todd A. Aguilera
The tumor landscape of pancreatic ductal adenocarcinoma (PDAC) is refractory to conventional photon radiotherapy (RT) because of a fibrotic tumor microenvironment (TME) that promotes chronic hypoxia and reduced immune surveillance. The radiobiological factors unique to carbon ion RT (CIRT), such as high linear energy transfer and less dependence on oxygen, make it well-suited to overcome the PDAC TME. In this study, we utilized clonal syngeneic KPC pancreatic tumor cell lines and tumors to examine this postulate and to identify underlying factors that affect the response of PDAC to CIRT. Although KPC cell lines exhibited radiobiological effectiveness greater than 3, subcutaneous tumors in the mouse hind leg showed lower radiobiological effectiveness—1.3 based on quintupling time—at a linear energy transfer between 70 and 80 keV/μm. Four days after CIRT, we observed widespread transcriptomic changes in the tumor immune microenvironment, suggesting increased infiltration of antitumor immune cells and elevated expression of antitumor T-cell cytokines, MHC class I molecules, and co-stimulatory signals. Fewer immunologic changes were observed following photon irradiation. By 7 days after CIRT, tumor-supportive transcriptomic programs characterized by protumor cytokines, M2 macrophages, and cancer-associated fibroblasts emerged, promoting resistance and limiting the durability of tumor growth delay. These findings suggest that CIRT may offer a favorable platform compared with conventional photon RT for combining with immunotherapies. Furthermore, these data highlight the risk of using in vitro survival data alone in treatment planning and indicate that underlying TME factors affect the response of PDAC in vivo.

4 February 2026
Verified
Other
Open access
KSKaty L. Swancutt
Katy L. Swancutt
EEEslam A. Elghonaimy
Eslam A. Elghonaimy
JNJames H. Nicholson
James H. Nicholson
Laurentiu M. PopLaurentiu M. Pop
Laurentiu M. Pop
BSBrock J. Sishc
Brock J. Sishc
TATodd A. Aguilera
Todd A. Aguilera
Table of genes categories and genes defining the category for Figure 2F.

4 February 2026
Verified
Other
Open access
KSKaty L. Swancutt
Katy L. Swancutt
EEEslam A. Elghonaimy
Eslam A. Elghonaimy
JNJames H. Nicholson
James H. Nicholson
Laurentiu M. PopLaurentiu M. Pop
Laurentiu M. Pop
BSBrock J. Sishc
Brock J. Sishc
TATodd A. Aguilera
Todd A. Aguilera
Supplementary Figure 3 shows cGas sting expression of various KPC clones and then carbon and photon treated KPC 36 implanted mouse response and survival.

4 February 2026
Verified
Other
Open access
KSKaty L. Swancutt
Katy L. Swancutt
EEEslam A. Elghonaimy
Eslam A. Elghonaimy
JNJames H. Nicholson
James H. Nicholson
Laurentiu M. PopLaurentiu M. Pop
Laurentiu M. Pop
BSBrock J. Sishc
Brock J. Sishc
TATodd A. Aguilera
Todd A. Aguilera
Raw data tables for sequencing data from figures 2 and 5.